Flputnam Investment Management Co. Purchases 53,552 Shares of Stryker Corporation $SYK

Key Points

• Flputnam Investment Management increased its Stryker stake by 64.1% in the second quarter, purchasing 53,552 shares and bringing its total holdings to 137,133 shares valued at approximately $43.2 million. Institutional investors collectively own 77.09% of Stryker.
• Stryker reported quarterly earnings of $3.69 per share, beating estimates of $3.49, while revenue rose 9.4% year over year to $6.59 billion. The company maintained fiscal 2026 EPS guidance of $14.95–$15.10.
• Analysts maintain a generally positive outlook, with a consensus “Moderate Buy” rating and a $386.28 target price versus the stock’s reported $331.32 price. Stryker also declared a quarterly dividend of $0.88 per share, equivalent to a 1.1% annual yield.

Flputnam Investment Management Co. increased its stake in Stryker Corporation (NYSE:SYK - Free Report) by 64.1% during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 137,133 shares of the medical technology company's stock after buying an additional 53,552 shares during the period. Flputnam Investment Management Co.'s holdings in Stryker were worth $43,175,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of SYK. Brighton Jones LLC lifted its position in Stryker by 15.4% in the fourth quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company's stock worth $1,643,000 after buying an additional 609 shares during the last quarter. Schnieders Capital Management LLC. acquired a new stake in shares of Stryker in the second quarter valued at about $205,000. Marshall Wace LLP lifted its stake in shares of Stryker by 107.9% in the second quarter. Marshall Wace LLP now owns 5,700 shares of the medical technology company's stock worth $2,255,000 after buying an additional 77,831 shares in the last quarter. Nebula Research & Development LLC purchased a new position in Stryker in the second quarter worth approximately $219,000. Finally, HUB Investment Partners LLC purchased a new stake in shares of Stryker in the 2nd quarter valued at approximately $253,000. Hedge funds and other institutional investors own 77.09% of the company's stock.

Insider Buying and Selling at Stryker

In other Stryker news, insider Debra King sold 826 shares of the business's stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $336.30, for a total value of $277,783.80. Following the completion of the sale, the insider owned 6,210 shares of the company's stock, valued at $2,088,423. The trade was a 11.74% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Dylan Bram Crotty sold 441 shares of the stock in a transaction that occurred on Friday, August 21st. The stock was sold at an average price of $328.61, for a total transaction of $144,917.01. Following the sale, the insider owned 6,102 shares in the company, valued at $2,005,178.22. This represents a 6.74% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 351,267 shares of company stock valued at $118,197,701 in the last ninety days. 4.60% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on SYK. BTIG Research decreased their target price on Stryker from $371.00 to $358.00 and set a "buy" rating for the company in a report on Friday, July 31st. Weiss Ratings reissued a "hold (c)" rating on shares of Stryker in a report on Friday, July 31st. Citigroup restated a "buy" rating on shares of Stryker in a research report on Thursday, August 13th. Truist Financial increased their price objective on shares of Stryker from $330.00 to $340.00 and gave the stock a "hold" rating in a research report on Friday, July 31st. Finally, Leerink Partners reduced their price objective on Stryker from $410.00 to $407.00 and set an "outperform" rating on the stock in a research note on Friday, June 5th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have issued a Hold rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $386.28.

Stryker Trading Up 2.9%

Shares of NYSE:SYK opened at $331.32 on Friday. Stryker Corporation has a 1 year low of $281.00 and a 1 year high of $396.86. The firm has a fifty day moving average price of $329.10 and a 200 day moving average price of $331.47. The company has a current ratio of 2.16, a quick ratio of 1.33 and a debt-to-equity ratio of 0.59. The stock has a market capitalization of $127.08 billion, a PE ratio of 34.33, a P/E/G ratio of 2.11 and a beta of 0.76.

Stryker (NYSE:SYK - Get Free Report) last released its earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share for the quarter, topping analysts' consensus estimates of $3.49 by $0.20. The business had revenue of $6.59 billion for the quarter, compared to the consensus estimate of $6.58 billion. Stryker had a return on equity of 23.63% and a net margin of 14.43%.The firm's revenue for the quarter was up 9.4% compared to the same quarter last year. During the same period last year, the business earned $3.13 earnings per share. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Analysts expect that Stryker Corporation will post 15.02 EPS for the current fiscal year.

Stryker Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be issued a $0.88 dividend. This represents a $3.52 annualized dividend and a yield of 1.1%. The ex-dividend date of this dividend is Wednesday, September 30th. Stryker's dividend payout ratio is currently 36.48%.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons' offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source